> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Nektar Moves Up Planned Hair-Loss Trial Start To December As Research Spending Rises
- URL: https://www.bullished.co/nektar-moves-up-planned-hair-loss-trial-start-to-december-as-research-spending-rises-7d91da83/
- Published: 2026-11-12T21:36:41.000Z
- Updated: 2026-11-12T21:36:41.000Z
- Description: The drug developer held $952.9 million in cash and investments as it advanced rezpegaldesleukin into late-stage testing.
- Author: Matteo Parrino
- Tags: SEC Filings, NKTR, Industry: Healthcare

[Nektar Therapeutics](https://www.bullished.co/tag/nktr/), which is testing rezpegaldesleukin for eczema and hair loss, plans to start its late-stage alopecia areata trial in December, ahead of its previous timetable. The company outlined the [earlier trial start](https://www.sec.gov/Archives/edgar/data/0000906709/000121390026118964/ea0311998-8k%5Fnektar.htm?ref=bullished.co) in Thursday’s earnings release accompanying its [8-K](https://www.bullished.co/learn/8-k-items-explained/), alongside $952.9 million in cash and marketable investments.

## December Start, 2028 Results

Howard Robin, Nektar’s president and chief executive officer, said the global hair-loss trial was on track for December, “earlier than previously planned,” in the [earnings release](https://www.sec.gov/Archives/edgar/data/0000906709/000121390026118964/ea031199801ex99-1.htm?ref=bullished.co).

Nektar expects initial results in summer 2028 and targets its first [FDA approval application](https://www.prnewswire.com/news-releases/nektar-therapeutics-announces-third-quarter-2026-financial-results-302938396.html?ref=bullished.co) in 2029\. Rezpegaldesleukin is an experimental injection intended to change immune responses; Nektar also develops other experimental medicines and licenses drug technologies to pharmaceutical and biotechnology companies.

The eczema program already has its late-stage trials underway. Nektar began the first trials in July and [announced the final](https://www.sec.gov/Archives/edgar/data/0000906709/000121390026118964/ea031199801ex99-1.htm?ref=bullished.co) trial in October, enrolling patients previously treated with biologic medicines or JAK inhibitors. The company aims to support a broad approved use for the drug.

Results from the earlier eczema study’s 16-week treatment period appeared in The Lancet in August. The study met its main and key secondary goals, including measures of eczema severity and itching.

## Hair Regrowth After Treatment Stopped

Nektar’s [October update](https://www.sec.gov/Archives/edgar/data/0000906709/000121390026105453/ea030730601ex99-1.htm?ref=bullished.co) provided follow-up evidence from patients with severe-to-very-severe alopecia areata. Among eight patients who reached the specified scalp-hair response threshold after 52 weeks of treatment, six, or 75%, retained that response four months after stopping treatment; five, or 63%, retained it at six months.

Hair regrowth continued during the six-month period without treatment. The proportion reaching the study’s stricter scalp-hair threshold rose to 19% from 7% at the end of treatment. Nektar said those findings support evaluating less frequent dosing for patients who achieve the response threshold.

## More Cash, Higher Trial Costs

Cash and marketable investments stood at [$952.9 million](https://www.prnewswire.com/news-releases/nektar-therapeutics-announces-third-quarter-2026-financial-results-302938396.html?ref=bullished.co) at September’s end, up from $245.8 million at the end of 2025.

Third-quarter research spending rose to $44.1 million from $27.3 million a year earlier. Nektar attributed the increase mainly to late-stage eczema and alopecia trials and rezpegaldesleukin manufacturing work. Research spending for the first nine months reached $118.9 million, versus $87.6 million a year earlier.

Administrative expenses increased to $24.6 million from $16.1 million in the quarter, primarily because of higher legal expenses, Nektar said. For the first nine months, administrative spending fell to $50.8 million from $57.5 million, which the company attributed mainly to lower legal expenses over that period.

Quarterly revenue declined to $9.4 million from $11.8 million and consisted entirely of non-cash royalties associated with future royalty rights Nektar previously sold. Nine-month revenue fell to $30.4 million from $33.4 million.

The quarterly net loss widened to $55.7 million from $35.5 million, while loss per share narrowed to $1.63 from $1.87\. The weighted-average share count used in that calculation was 34,178,219, versus 18,946,559 a year earlier. For the first nine months, the net loss rose to $141.2 million from $128.0 million, with per-share losses of $4.60 versus $8.14.

December is the planned start for the hair-loss trial; Nektar’s next stated initial-results milestone is summer 2028.

Learn

- [Item 2.02: results of operations →](https://www.bullished.co/learn/8-k-items-explained/#item-202-results-of-operations)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — NEKTAR THERAPEUTICS (NKTR)](https://www.sec.gov/Archives/edgar/data/0000906709/000121390026118964/ea0311998-8k%5Fnektar.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit ea031199801ex99-1.htm — NEKTAR THERAPEUTICS 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0000906709/000121390026118964/ea031199801ex99-1.htm?ref=bullished.co) — SEC EDGAR
- [How New Eczema Drug Trials Will Impact Nektar Therapeutics (NKTR) Investors](https://finance.yahoo.com/healthcare/articles/eczema-drug-trials-impact-nektar-221227221.html?ref=bullished.co) — Yahoo Finance
- [Nektar Therapeutics Announces Third Quarter 2026 Financial Results](https://www.prnewswire.com/news-releases/nektar-therapeutics-announces-third-quarter-2026-financial-results-302938396.html?ref=bullished.co) — prnewswire.com
- [Nektar Therapeutics to Participate in Two Investor Conferences in November](https://www.prnewswire.com/news-releases/nektar-therapeutics-to-participate-in-two-investor-conferences-in-november-302936871.html?ref=bullished.co) — prnewswire.com
- [8-K filed 2026-10-01 — NEKTAR THERAPEUTICS (earlier disclosure)](https://www.sec.gov/Archives/edgar/data/0000906709/000121390026105453/ea030730601ex99-1.htm?ref=bullished.co) — SEC EDGAR

### More on Nektar Therapeutics

- [State Street Holds 5.2% Of Nektar — It Isn't Seeking To Change Control](https://www.bullished.co/state-street-holds-5-2-of-nektar-it-isnt-seeking-to-change-control-ee480764/)

[All Nektar Therapeutics (NKTR) coverage →](https://www.bullished.co/tag/nktr/)